Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's launch map; Samsung Bio's growth plans
As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...
GlobalData on MSN14d
AbbVie and Simcere Zaiming link to develop trispecific antibodyThe humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory MM.
Zacks.com on MSN5d
AbbVie Inks a Deal With Neomorph for Molecular Glue DegradersPer the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and ...
AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and ...
Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.
Insider Monkey on MSN11d
Why Is AbbVie Inc. (ABBV) Among Louis Navellier’s Top Long-term Stock Picks?Louis Navellier is a prominent American investor, author, and financial analyst, best known for his quantitative approach to ...
We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...
AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback